Ascendis Pharma A/S Stock News

Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism Clinical data demonstrate the potential of TransCon PTH as a hormone replace

COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidat

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2020 Results - Earnings Call Transcript

– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track –

COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical n

COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidat

COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs

COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate

If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances t

COPENHAGEN, Denmark, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate

– Advances Vision 3x3 to extend global clinical and commercial reach –

COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate

- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response  -

Investors need to pay close attention to Ascendis Pharma (ASND) stock based on the movements in the options market lately.

– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting –